2011
1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism
Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, Sanacora G. 1H-[13C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. Biological Psychiatry 2011, 71: 1022-1025. PMID: 22169441, PMCID: PMC3660962, DOI: 10.1016/j.biopsych.2011.11.006.Peer-Reviewed Original ResearchConceptsMedial prefrontal cortexSubanesthetic dosesAcute effectsNeurotransmitter cyclingMagnetic resonance spectroscopy measuresMPFC of ratsPotential physiological processesAntidepressant-like propertiesSaline-treated animalsAmino acid neurotransmittersHippocampus of ratsDose of ketamineEffects of ketamineGlial energy metabolismMPFC levelsGlutamate releaseKetamine effectsΓ-aminobutyric acidGlial metabolismKetaminePrefrontal cortexEnrichment of glutamateVivo studiesEnergy metabolismRats
2008
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 2008, 7: 426-437. PMID: 18425072, PMCID: PMC2715836, DOI: 10.1038/nrd2462.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsExcitatory Amino Acid AntagonistsGlutamatesHumansMood DisordersPsychotropic DrugsConceptsGlutamatergic systemMood disordersAntidepressant effectsNMDA antagonistsDouble-blind placebo-controlled crossover studyTreatment-resistant major depressive disorderPlacebo-controlled crossover studyGlutamate release inhibitorSignificant antidepressant effectNMDA receptor expressionRecurrent mental illnessSingle intravenous doseMajor depressive disorderPotential novel therapeuticsGlutamatergic abnormalitiesCrossover studyGlutamate releaseIntravenous doseMood stabilizersDepressive disorderReceptor expressionReceptor modulatorsEvidence of alterationsCerebrospinal fluidAMPA potentiators
2001
ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment
Chen A, Shin K, Duman R, Sanacora G. ECS-Induced Mossy Fiber Sprouting and BDNF Expression Are Attenuated By Ketamine Pretreatment. Journal Of Ect 2001, 17: 27-32. PMID: 11281511, DOI: 10.1097/00124509-200103000-00006.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain-Derived Neurotrophic FactorElectroconvulsive TherapyExcitatory Amino Acid AntagonistsKetamineMaleMossy Fibers, HippocampalRatsRats, Sprague-DawleyReceptors, N-Methyl-D-AspartateConceptsNeurotrophic factor expressionMossy fiber sproutingBDNF expressionElectroconvulsive seizuresKetamine pretreatmentSeizure durationFiber sproutingDentate gyrusBrain-derived neurotrophic factor (BDNF) expressionFactor expressionChronic electroconvulsive seizureSpecific anesthetic agentsTreatment of depressionNMDA receptor activationMossy fiber pathwayUse of ECTMedial prefrontal cortexTimm histochemistryCortical atrophySeizure intensitySeizure activityMajor depressionNMDA antagonistsNMDA receptorsAnesthetic agents